GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis
Digestive Diseases · 2026-11-09
DOI: 10.1159/ddi/acnag020 ↗Abstract
Abstract Background: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with high unmet therapeutic need. GLP-1/glucagon dual receptor agonists are an emerging drug class, but no meta-analysis has evaluated it exclusively. Methods: In this registered systematic review and meta-analysis (PROSPERO CRD420261325731), we searched PubMed, Embase, Cochrane, and Google Scholar through January 2026 for placebo-controlled randomized trials of GLP-1/glucagon dual agonists in adults with MASH or MASLD. Four trials (survodutide, pemvidutide, cotadutide; n=673) were pooled with DerSimonian-Laird random-effects models; Hartung-Knapp-Sidik-Jonkman adjustment was a sensitivity analysis. Results: Dual agonists increased MASH resolution without worsening of fibrosis (RR 2.98, 95% CI 2.09–4.24; k=2). A borderline, exploratory signal for fibrosis improvement was observed (RR 1.38, 95% CI 1.01–1.88; p=0.044; k=2); neither trial was individually significant. Relative liver fat fell by 46.24% (95% CI −55.24 to −37.24), and ≥30% liver fat reduction was more frequent (RR 4.39, 95% CI 2.97–6.49). ALT (MD −20.38 IU/L, 95% CI −33.00 to −7.75), AST (MD −18.80 IU/L), body weight (MD −4.36%) and systolic blood pressure (MD −5.22 mmHg) decreased; the ELF reduction was not retained in sensitivity analyses. Nausea (RR 2.90), vomiting (RR 9.58) and diarrhea (RR 1.90) were more frequent; serious adverse events were not (RR 1.06). Split-placebo analyses were consistent. Conclusions: Dual agonists were associated with a higher likelihood of MASH resolution, a borderline exploratory fibrosis signal, and reductions in liver fat, liver enzymes, weight and systolic blood pressure, with more gastrointestinal adverse events. These early-phase findings support continued Phase 3 evaluation.
EUVIMED